Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free HLS Stock Alerts

HLS Therapeutics (HLS) Competitors

HLS Therapeutics logo
C$4.20 -0.05 (-1.18%)
As of 07/3/2026 03:50 PM Eastern
Compare

HLS vs. CPH, FIRE, ACB, EPI, and ICC

Should you buy HLS Therapeutics stock or one of its competitors? MarketBeat compares HLS Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HLS Therapeutics include Cipher Pharmaceuticals (CPH), Supreme Cannabis (FIRE), Aurora Cannabis (ACB), ESSA Pharma (EPI), and ICC Labs (ICC). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

HLS Therapeutics (TSE:HLS) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

HLS Therapeutics presently has a consensus target price of C$6.00, indicating a potential upside of 42.86%. Cipher Pharmaceuticals has a consensus target price of C$17.00, indicating a potential downside of 0.99%. Given HLS Therapeutics' higher possible upside, equities analysts plainly believe HLS Therapeutics is more favorable than Cipher Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cipher Pharmaceuticals has a net margin of 60.82% compared to HLS Therapeutics' net margin of -18.42%. Cipher Pharmaceuticals' return on equity of 25.69% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
Cipher Pharmaceuticals 60.82%25.69%7.90%

HLS Therapeutics has a beta of -0.152102, suggesting that its share price is 115% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.104631, suggesting that its share price is 10% more volatile than the broader market.

5.4% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cipher Pharmaceuticals has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.36-C$15.53M-C$0.32N/A
Cipher PharmaceuticalsC$50.94M8.56C$11.41MC$1.1914.43

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
Cipher Pharmaceuticals Neutral

Summary

Cipher Pharmaceuticals beats HLS Therapeutics on 10 of the 13 factors compared between the two stocks.

How does HLS Therapeutics compare to Supreme Cannabis?

HLS Therapeutics (TSE:HLS) and Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Supreme Cannabis has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. Supreme Cannabis' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
Supreme Cannabis N/A N/A N/A

HLS Therapeutics has higher revenue and earnings than Supreme Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.36-C$15.53M-C$0.32N/A
Supreme CannabisC$53.29M0.00-C$23.65M-C$0.03N/A

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled Supreme Cannabis'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
Supreme Cannabis Neutral

5.4% of HLS Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Supreme Cannabis beats HLS Therapeutics on 5 of the 9 factors compared between the two stocks.

How does HLS Therapeutics compare to Aurora Cannabis?

Aurora Cannabis (TSE:ACB) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

4.1% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 5.4% of HLS Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aurora Cannabis has a beta of 0.174133, suggesting that its share price is 83% less volatile than the broader market. Comparatively, HLS Therapeutics has a beta of -0.152102, suggesting that its share price is 115% less volatile than the broader market.

Aurora Cannabis presently has a consensus target price of C$7.17, indicating a potential upside of 75.22%. HLS Therapeutics has a consensus target price of C$6.00, indicating a potential upside of 42.86%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aurora Cannabis is more favorable than HLS Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Aurora Cannabis has a net margin of -12.13% compared to HLS Therapeutics' net margin of -18.42%. Aurora Cannabis' return on equity of -7.25% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-12.13% -7.25% -1.87%
HLS Therapeutics -18.42%-16.54%-2.89%

HLS Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$320.59M0.79-C$44.16M-C$2.14N/A
HLS TherapeuticsC$55.74M2.36-C$15.53M-C$0.32N/A

In the previous week, Aurora Cannabis had 1 more articles in the media than HLS Therapeutics. MarketBeat recorded 1 mentions for Aurora Cannabis and 0 mentions for HLS Therapeutics. HLS Therapeutics' average media sentiment score of 0.00 beat Aurora Cannabis' score of -1.00 indicating that HLS Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aurora Cannabis Negative
HLS Therapeutics Neutral

Summary

Aurora Cannabis beats HLS Therapeutics on 10 of the 16 factors compared between the two stocks.

How does HLS Therapeutics compare to ESSA Pharma?

ESSA Pharma (CVE:EPI) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

ESSA Pharma has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. ESSA Pharma's return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ESSA PharmaN/A N/A N/A
HLS Therapeutics -18.42%-16.54%-2.89%

5.4% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ESSA Pharma has higher earnings, but lower revenue than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ESSA PharmaN/AN/AN/A-C$0.99N/A
HLS TherapeuticsC$55.74M2.36-C$15.53M-C$0.32N/A

In the previous week, ESSA Pharma's average media sentiment score of 0.00 equaled HLS Therapeutics'average media sentiment score.

Company Overall Sentiment
ESSA Pharma Neutral
HLS Therapeutics Neutral

Summary

ESSA Pharma and HLS Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does HLS Therapeutics compare to ICC Labs?

HLS Therapeutics (TSE:HLS) and ICC Labs (CVE:ICC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

ICC Labs has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.36-C$15.53M-C$0.32N/A
ICC LabsC$533.68K419.04C$2.35MC$0.0295.29

5.4% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled ICC Labs'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
ICC Labs Neutral

ICC Labs has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. ICC Labs' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
ICC Labs N/A N/A N/A

Summary

ICC Labs beats HLS Therapeutics on 7 of the 10 factors compared between the two stocks.

Get HLS Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HLS vs. The Competition

Export
MetricHLS TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$132.92MC$6.60BC$7.18BC$13.07B
Dividend Yield4.30%2.83%2.66%6.18%
P/E Ratio-13.135.1128.0236.51
Price / Sales2.361,653.39538.9910.34
Price / Cash15.2210.1849.2682.29
Price / Book2.2410.8310.964.52
Net Income-C$15.53MC$20.27BC$3.57BC$299.09M
7 Day Performance1.45%1.30%2.12%1.85%
1 Month Performance-6.04%-1.17%5.25%1.71%
1 Year Performance-14.98%9.82%33.29%36.40%

HLS Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HLS
HLS Therapeutics
N/AC$4.20
-1.2%		C$6.00
+42.9%		-15.0%C$132.92MC$55.74MN/A91
CPH
Cipher Pharmaceuticals
N/AC$16.75
+0.2%		C$17.00
+1.5%		+26.5%C$425.30MC$50.94M14.085
FIRE
Supreme Cannabis
N/AN/AN/AN/AC$259.40MC$53.29MN/A400
ACB
Aurora Cannabis
2.1001 of 5 stars		C$3.99
+1.5%		C$7.67
+92.1%		-34.1%C$247.15MC$320.59MN/A1,073
EPI
ESSA Pharma
N/AC$8.20
+7.2%		N/A+0.0%C$237.87MN/AN/A25

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HLS) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel